Bullish & Foolish
--
--

Is Palatin Technologies going out of business?

Loading the full analysis
Reading the filings

PALATIN TECHNOLOGIES, INC. (PTN) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

PALATIN TECHNOLOGIES, INC. (PTN) scores 14 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Quality score 14/100
Rating Distressed / Caution
Sector Biotech/Pharma
Market cap $22.6M
Last close $12.70
Revenue growth (YoY) 3476.2%
Dividend yield 0.0%

Leading signal: Shares dilution YoY: 453.81% (YoY)

Five questions, kept separate

Survival - Critical
4-7 mo of estimated runway from 2026-03-31, based on $10.2M of cash and short-term investments against $21.3M of annual burn. Adjusted shares outstanding increased 453.8% over the comparison year.
Business quality - Pre-commercial
Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.
Trajectory - Clinical progress unavailable
Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.
Valuation - Demanding
9.4% net-cash backing support a demanding pre-commercial Valuation assessment.
Event risk - Evidence unavailable
No active asserted adverse event was found in the available filing evidence. The filing evidence is stale or incomplete, so this is not proof of absence.

What the rules read

  • Shares dilution YoY: 453.81% (YoY)
  • Debt / Equity: -0.93x (Net Cash)
  • Interest coverage: -707.4x
  • Cash Runway (years): 0.48y
  • Revenue CAGR (3Y): -100.00%
  • Return on Assets: -130.87%
  • Cash Burn Deceleration: 94.99% QoQ improvement (Rapid improvement)
  • FCF margin: -277.88% (Inv. Mode)
  • Price / Earnings: Unprofitable (see Valuation)

Read from filings through 2026-05-13.

Price as of 2026-09-07.

Headline score detail

Source coverage and limitations
--
Reference Links